Because patients who are treated with 5 μg/d or 0 μg/d of calcitriol tend to develop FTY720 hypercalcinuria, serum and urinary calcium levels should be examined regularly, and the calcitriol regime should be examined intermittently. Patients are frequently treated with 25 μg/d of calcitriol in China, especially elderly patients with osteoporosis. Hurst et al concluded that correcting vitamin D deficiency in older women may suppress the age-induced acceleration in bone turnover and may reduce bone resorption.
However, Seemans et al observed that despite the stratifica tion of different vitamin D Icariin receptor genotypes, cholecalciferol supplementation throughout the winter months did not affect bone turnover markers in young or old people. The aim of the current study was to compare the effects of cholecalciferol at IU per day and calcitriol at 25 μg per day on calcium metabolism and bone turnover in Chinese postmenopausal women who are vitamin D insufficient. Materials and methods Subjects and study design This was an open-label, controlled clinical trial. The study was approved by the Ethics Committee of the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. One hundred healthy, independent, ambulatory, postmenopausal female volunteers were recruited from community centers. All participants were of Han ethnicity and had lived in Shanghai for purchase Finibax more than 30 years. Postmenopausal women over 50 years of age were eligible for the study, and the serum 25D concentrations of all subjects were less than 30 ng/mL.
All subjects were given a physical examination and were found to be in good health. No participant was receiving treatment or had medical complications that were known to order LY450139 affect bone metabolism, including hyperthyroidism, diabetes mellitus, primary hyperparathyroidism, renal failure, pituitary diseases, and adrenal diseases. All the women had taken less than mg/day of calcium and less than IU/day of vitamin D within the 3 months prior to enrollment. The subjects were divided into two groups based on age and serum 25D concentrations. Fifty of the subjects Acta Pharmacologica Sinica received IU/day of cholecalciferol , and the other fifty matched subjects received 25 μg/day of calcitriol , as group A and group B, respectively. All subjects received 1 pill/day of Caltrate D . Because the Caltrate D contained IU of vitamin D 3 , group A was provided IU of cholecalciferol altogether. The study period was from December 9 to March 0, which was during the end of winter and the beginning of spring in China. Laboratory tests ribosome Fasting blood samples were obtained at baseline and at the end of the study.
Blood routine, erythrosedimentation, liver function, renal function and fasting blood-glucose were examined to exclude subjects who had other factors that may affect their vitamin D status. Markers of calcium metabolism and bone turnover were assessed before and after the three-month intervention, including serum calcium.